REFRACTORY PANCREATIC DUCTAL ADENOCARCINOMA

Clinical trials for REFRACTORY PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY PANCREATIC DUCTAL ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for REFRACTORY PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for Tough-to-Treat pancreatic cancer?

Disease control Not yet recruiting

This study is testing a new two-drug combination (JDB153 and serplulimab) for people with advanced pancreatic cancer that has worsened despite standard treatments. The main goals are to see if the treatment is safe and if it can shrink tumors. It will involve about 10 participant…

Matched conditions: REFRACTORY PANCREATIC DUCTAL ADENOCARCINOMA

Phase: PHASE1, PHASE2 • Sponsor: West China Hospital • Aim: Disease control

Last updated Mar 27, 2026 12:38 UTC

REFRACTORY PANCREATIC DUCTAL ADENOCARCINOMA

Get alerted when new REFRACTORY PANCREATIC DUCTAL ADENOCARCINOMA trials appear

New hope for Tough-to-Treat pancreatic cancer?